FDA Warning Letter to Active Cosmetics Manufacturing Inc. (2026-04-22) — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
The short version: FDA issued a Warning Letter to Active Cosmetics Manufacturing Inc. on 2026-04-22 citing: CGMP/Finished Pharmaceuticals/Adulterated. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/active-cosmetics-manufacturing-inc-722408-04222026
Argus analysis
Active Cosmetics Manufacturing Inc. (MARCS-CMS 722408, FEI 3005351079) received an FDA Warning Letter dated April 22, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: CGMP/Finished Pharmaceuticals/Adulterated. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on May 5, 2026.
CGMP citations typically reference 21 CFR Part 211 (finished pharmaceuticals) or Part 111 (dietary supplements), covering subjects such as identity testing of incoming components, validated cleaning procedures, batch-failure investigations, and stability program design. Repeat or systemic findings are what typically drive FDA toward import alert or consent decree escalation.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same CGMP (Current Good Manufacturing Practice) category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Active Cosmetics Manufacturing Inc. MARCS-CMS 722408 — April 22, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-71 Product: Drugs Recipient: Recipient Name Ms. Celia Ferreira Recipient Title CEO Active Cosmetics Manufacturing Inc. 7075 Kingspointe Parkway, Suites 2, 3, 4, and 5 Orlando , FL 32819-6540 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-71 April 22, 2026 Dear Ms. Ferreira: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Active Cosmetics Manufacturing Inc., FEI 3005351079, at 7075 Kingspointe Parkway, Suites 2, 3, 4, and 5, Orlando, from October 27 to 31, 2025. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your November 21, 2025 response to our Form FDA 483 in detail. During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). You manufacture topical over-the-counter (OTC) drug products, including (b)(4) labeled for use in (b)(4) . You failed to adequately investigate out-of-specification (OOS) microbiological test results of your drug products. You released batches for commercial distribution based on passing retest results, without conducting thorough investigations to determine the root causes of the original results. For example: Batch (b)(4) was found to contain the objectionable microorganism Staphylococcus aureus . Batch (b)(4) was found to contain the objectionable microorganism Pseudomonas aeruginosa . Batch (b)(4) failed the Neogen Soleris Next Generation System test that you claimed assesses total viable count. Passing retest results alone cannot serve as the basis for invalidating OOS results. As a manufacturer, you have a responsibility to fully investigate aberrant microbial test results that may impact drug product quality. In addition, investigations into microbial contamination should include awareness that microbial contamination is not uniformly distributed. These findings are indicative of a lack of state of control of your manufacturing processes. We note that your firm has not performed process validation studies to determin…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has Active Cosmetics Manufacturing Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Active Cosmetics Manufacturing Inc. as of 2026-05-05. Argus ingests new FDA enforcement records daily.
- What FDA violations was Active Cosmetics Manufacturing Inc. cited for?
- The FDA Warning Letter to Active Cosmetics Manufacturing Inc. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Active Cosmetics Manufacturing Inc.?
- FDA issued the letter (MARCS-CMS 722408) on 2026-04-22 and posted it publicly on fda.gov on 2026-05-05.
- Is the FDA warning letter to Active Cosmetics Manufacturing Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/active-cosmetics-manufacturing-inc-722408-04222026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to Active Cosmetics Manufacturing Inc. (2026-04-22) — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-active-cosmetics-manufacturing-inc-2026-04-22-cgmp
"FDA Warning Letter to Active Cosmetics Manufacturing Inc. (2026-04-22) — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-active-cosmetics-manufacturing-inc-2026-04-22-cgmp.
Argus HQ Research. "FDA Warning Letter to Active Cosmetics Manufacturing Inc. (2026-04-22) — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-active-cosmetics-manufacturing-inc-2026-04-22-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_active_cosmetics_manufacturing_inc_2026_04_22_cgmp_2026,
title = {FDA Warning Letter to Active Cosmetics Manufacturing Inc. (2026-04-22) — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-active-cosmetics-manufacturing-inc-2026-04-22-cgmp},
note = {Accessed: July 13, 2026}
}